<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;ARSA &lt;/i&gt;(metachromatic leukodystrophy gene)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>ARSA </i>(metachromatic leukodystrophy gene)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>ARSA </i>(metachromatic leukodystrophy gene)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April L Studinski, MS, CGC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1444267585"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph discusses implications of genetic test results for the <em>ARSA</em> gene. <em>ARSA</em> encodes arylsulfatase A, deficiency of which causes metachromatic leukodystrophy (MLD), a lysosomal disease characterized by progressive and ultimately fatal neurodegeneration.</p><p>Indications for <em>ARSA</em> genetic testing and care of the tested individual are discussed separately [<a href="#rid1">1</a>]. (See <a class="local">'Resources'</a> below.)</p><p class="headingAnchor" id="H2056660082"><span class="h1">BACKGROUND</span></p><p class="headingAnchor" id="H3618695456"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>The table summarizes considerations for reviewing the genetic test report, including the importance of obtaining a hard copy, verifying the correct individual was tested, and reviewing which gene(s) and which variant(s) in those genes were analyzed  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>). Coding DNA variants are designated with a "c"; variants in protein sequence are designated with a "p" followed by the specific change. </p><p>Testing for clinical care should be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or other nationally certified laboratory. If initial testing was not done in a clinically certified laboratory and results will impact clinical decision-making, testing should be repeated in a certified laboratory. This includes positive results (expected or unexpected) or negative results in an individual at risk due to family history or clinical suspicion for carrying a pathogenic variant in a leukodystrophy gene.</p><p>The glossary summarizes terms that may be used in the report  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 2</a>). Additional terms are defined separately. (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p class="headingAnchor" id="H3850050333"><span class="h2"><i>ARSA </i>gene</span><span class="headingEndMark"> — </span><em>ARSA </em>encodes arylsulfatase A, an enzyme that removes sulfate molecules from cerebroside sulfate, a myelin glycolipid. When enzyme activity is severely reduced, cerebroside sulfate accumulates, initially in lysosomes and eventually in other cellular compartments [<a href="#rid2">2</a>]. This accumulation causes lysosomal dysfunction and cell death, affecting oligodendroglial cells, some neurons, macrophages, and Schwann cells. The result is demyelination and neurodegeneration, with progressive functional decline. Other cell types such as gallbladder cells can also be affected.</p><p class="headingAnchor" id="H3175056323"><span class="h3">Common variants</span><span class="headingEndMark"> — </span>MLD is rare, although some populations have higher disease frequencies [<a href="#rid2">2</a>]. (See <a class="local">'Metachromatic leukodystrophy'</a> below.)</p><p>Hundreds of <em>ARSA</em> pathogenic variants have been described; they may be null or hypomorphic alleles. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Null alleles</strong> – Null alleles (also called "0" alleles) are pathogenic variants that completely abolish enzyme activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomorphic alleles</strong> – Hypomorphic alleles (also called "R" [for residual] alleles) are pathogenic variants that cause reduced but not absent enzyme activity.</p><p></p><p>The remainder of MLD cases are due to variants in the <em>PSAP</em> gene (&gt;60 described) [<a href="#rid3">3</a>]. PSAP encodes prosaposin (pSap), a precursor protein that can be cleaved to generate four saposins: SapA, SapB, SapC, and SapD [<a href="#rid2">2</a>]. Pathogenic variants in PSAP can cause either a single saposin deficiency or a deficiency of the entire pSap protein. Deficiency of SapB, which activates sphingolipids, results in an MLD phenotype [<a href="#rid2">2</a>]. Additional leukodystrophies have other genetic causes. (See  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Lysosomal diseases'</a> and  <a class="medical medical_review" href="/d/html/6177.html" rel="external">"Differential diagnosis of acute central nervous system demyelination in children", section on 'Leukodystrophies'</a>.)</p><p class="headingAnchor" id="H2023202223"><span class="h3">Pseudodeficiency alleles</span><span class="headingEndMark"> — </span>Pseudodeficiency alleles are variants in the <em>ARSA</em> gene (also called <em>ARSA</em>-PD) that cause reduced enzyme activity but do not cause clinical disease, even when co-inherited with a pathogenic variant on the other <em>ARSA</em> allele [<a href="#rid4">4</a>]. Screening for pseudodeficiency alleles is important when low but not absent arylsulfatase A levels are detected.</p><p>Examples of pseudodeficiency alleles include [<a href="#rid5">5</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>c.*96A&gt;G (an abnormality of polyadenylation)</p><p class="bulletIndent1"><span class="glyph">●</span>c.1055A&gt;G, p.(Asn352Ser), also referred to as c.1049A&gt;G or p.(Asn350Ser)</p><p class="bulletIndent1"><span class="glyph">●</span>c.1524+95A&gt;G </p><p class="bulletIndent1"><span class="glyph">●</span>Two variants together in cis on the same allele</p><p></p><p>Pseudodeficiency alleles are common in the general population (frequency 1 to 2 percent or more in some populations) [<a href="#rid6">6</a>]. They can complicate interpretation of genetic test results. Biochemical confirmation with enzyme testing and urine sulfatides is essential to determine whether individuals with these alleles have arylsulfatase A deficiency and are at risk for clinical disease. Typically, pseudodeficiency is suggested by leukocyte arylsulfatase A activity of 5 to 20 percent of control, although urine sulfatides or genetic testing is necessary to differentiate pseudodeficiency from disease [<a href="#rid7">7</a>].</p><p>Consultation with a genetics expert or disease expert is essential.</p><p class="headingAnchor" id="H1518738401"><span class="h3">Genotype-phenotype correlation</span><span class="headingEndMark"> — </span>The type of pathogenic variant determines the amount of residual arylsulfatase A activity, which in turn determines the age of onset and rate of disease progression [<a href="#rid2">2,8</a>].</p><p>There are three main presentations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late infantile</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most common</p><p class="bulletIndent2"><span class="glyph">•</span>Biallelic null variants</p><p class="bulletIndent2"><span class="glyph">•</span>Onset before age three years</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive weakness, hypotonia, loss of milestones, language and cognitive decline</p><p class="bulletIndent2"><span class="glyph">•</span>Final stages of disease characterized by seizures, spasticity, and loss of cognition</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Juvenile</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One null variant and one hypomorphic variant</p><p class="bulletIndent2"><span class="glyph">•</span>Onset from age 3 to 16 years</p><p class="bulletIndent2"><span class="glyph">•</span>Behavioral changes, declining school performance, and gait disturbance</p><p class="bulletIndent2"><span class="glyph">•</span>Progression similar to late infantile form but slower</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adult</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Least common</p><p class="bulletIndent2"><span class="glyph">•</span>Biallelic hypomorphic variants</p><p class="bulletIndent2"><span class="glyph">•</span>Onset after 16 years</p><p class="bulletIndent2"><span class="glyph">•</span>Neuropsychiatric findings (mood disorders, psychotic symptoms, dementia, seizures)</p><p class="bulletIndent2"><span class="glyph">•</span>May be misdiagnosed as other disorders or as primary dementia, schizophrenia, or seizure disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Life expectancy 20 to 30 years after diagnosis</p><p></p><p>The full extent of genotype-phenotype relationships is incompletely understood. Some individuals from the same kindred who carry the same pathogenic variants have differing clinical features [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H1777442645"><span class="h3">Epidemiology and inheritance</span><span class="headingEndMark"> — </span>MLD is a rare disease but one of the more common leukodystrophies. The prevalence is estimated at approximately 1 in 40,000 to 1 in 160,000 [<a href="#rid2">2</a>]. Certain populations have much higher disease prevalence:</p><p class="bulletIndent1"><span class="glyph">●</span>Arab groups in Israel – 1 in 8000</p><p class="bulletIndent1"><span class="glyph">●</span>Navajo peoples – 1 in 2500</p><p class="bulletIndent1"><span class="glyph">●</span>Habbani Jewish people – 1 in 75</p><p></p><p>Inheritance is autosomal recessive. As little as 10 to 15 percent of normal arylsulfatase A activity is sufficient for normal neurologic functioning. Generally, MLD occurs with biallelic <em>ARSA</em> disease variants; heterozygosity for an <em>ARSA</em> pathogenic variant is an unaffected carrier state.</p><p class="headingAnchor" id="H2136903336"><span class="h2">Metachromatic leukodystrophy</span><span class="headingEndMark"> — </span>Metachromatic leukodystrophy (MLD, also called sulfatide lipidosis) is a lysosomal disease with accumulation of sulfatides, a common component of myelin. MLD causes demyelination in the central and peripheral nervous system. Progressive neurodegeneration impairs motor and cognitive function and is ultimately fatal [<a href="#rid9">9</a>]. </p><p>There are three types of presentations (late infantile, juvenile, adult) that correlate with the severity of arylsulfatase A deficiency. (See <a class="local">'Genotype-phenotype correlation'</a> above.)</p><p>Early diagnosis may increase access to investigational therapies or gene therapy. (See <a class="local">'Treatment'</a> below.)</p><p>Addition of <em>ARSA </em>gene testing to newborn screening panels has been discussed and is being used in limited regions. (See  <a class="medical medical_review" href="/d/html/4980.html" rel="external">"Overview of newborn screening"</a> and  <a class="medical medical_review" href="/d/html/6195.html" rel="external">"Metachromatic leukodystrophy", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2779361941"><span class="h1">IMPLICATIONS FOR DIAGNOSIS AND MANAGEMENT</span></p><p class="headingAnchor" id="H2829928769"><span class="h2">Pathogenic variant(s) in <i>ARSA</i></span><span class="headingEndMark"> — </span>MLD is an autosomal recessive disorder. (See <a class="local">'Epidemiology and inheritance'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biallelic variants </strong>– Individuals with biallelic (homozygous or compound heterozygous) pathogenic variants in <em>ARSA</em> have, or will develop, MLD  (<a class="graphic graphic_algorithm graphicRef139578" href="/d/graphic/139578.html" rel="external">algorithm 1</a>). Their evaluation and management should be performed by, or in consultation with, an expert in hereditary lysosomal diseases, neurodegenerative conditions, or MLD. (See <a class="local">'Evaluations and monitoring'</a> below and <a class="local">'Treatment'</a> below and <a class="local">'Resources'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoallelic variants</strong> – Individuals who are heterozygous for a pathogenic variant are unaffected carriers who may benefit from genetic counseling. (See <a class="local">'Considerations for relatives'</a> below.)</p><p></p><p class="headingAnchor" id="H596367837"><span class="h3">Evaluations and monitoring</span><span class="headingEndMark"> — </span>The diagnosis of MLD uses a combination of:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical findings</p><p class="bulletIndent1"><span class="glyph">●</span>Brain imaging (usually magnetic resonance imaging [MRI])</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of arylsulfatase A enzyme activity for biochemical confirmation</p><p class="bulletIndent1"><span class="glyph">●</span>Analysis of urine sulfatides for biochemical confirmation</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing</p><p></p><p>Biochemical tests of enzyme activity can be performed on skin fibroblasts, white blood cells (WBCs), or urine  (<a class="graphic graphic_algorithm graphicRef139578" href="/d/graphic/139578.html" rel="external">algorithm 1</a>). </p><p>Prenatal diagnosis can be performed by genetic testing. (See <a class="local">'Reproductive counseling'</a> below.)</p><p>Regular follow-up and monitoring of clinical status are important to identify needs for supportive care. This includes multidisciplinary monitoring of neurologic function (including development and cognitive function, motor function, gait, swallowing, and presence of seizures), feeding and nutritional status, and general physical health related to mobility, with monitoring for contractures. Hearing and vision may also be assessed and serial MRI scans may be performed [<a href="#rid7">7</a>]. </p><p>Individuals who undergo hematopoietic stem cell transplant, with or without gene therapy, require specialized monitoring. (See  <a class="medical medical_review" href="/d/html/6195.html" rel="external">"Metachromatic leukodystrophy", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2690787085"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Without treatment, progressive neurologic deterioration is eventually fatal.</p><p>Several therapies are under development that have the potential to alter disease course. Participation in a clinical trial for disease-modifying therapy is encouraged. The following types of therapies are at various stages of study and availability:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allogeneic hematopoietic stem cell transplant</strong> – Allogeneic transplantation can be performed using bone marrow, peripheral blood stem cells, or umbilical cord blood from a human leukocyte antigen (HLA)-matched donor. This can slow progression of central nervous system (CNS) disease but not peripheral nervous system abnormalities. It cannot reverse demyelination and is ineffective in some individuals. It is most appropriate for individuals who have not yet developed major disease manifestations. (See  <a class="medical medical_review" href="/d/html/6195.html" rel="external">"Metachromatic leukodystrophy", section on 'Hematopoietic stem cell transplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene therapy</strong> – Gene therapy has been approved in Europe using transduction of the <em>ARSA</em> gene into autologous hematopoietic stem cells and autologous hematopoietic stem cell transplantation. (See  <a class="medical medical_review" href="/d/html/6195.html" rel="external">"Metachromatic leukodystrophy", section on 'Ex vivo gene therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enzyme replacement</strong> – Enzyme replacement therapy and substrate reduction therapy have been investigated but have not been demonstrated to appreciably slow disease progression. This may be due to difficulty in the enzyme reaching the correct cells in the CNS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other investigational approaches</strong> – Therapies under study include cellular therapy, modified enzyme products with greater CNS penetration, injection of gene therapy constructs directly into the CNS, and antiinflammatory medications [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H1625810321"><span class="h2">Variant of uncertain significance (VUS)</span><span class="headingEndMark"> — </span>If an individual has a pathogenic variant affecting one allele and a VUS affecting the other allele (or a VUS at both alleles), together with a clinical picture suggestive of MLD, biochemical testing becomes especially important  (<a class="graphic graphic_algorithm graphicRef139578" href="/d/graphic/139578.html" rel="external">algorithm 1</a>). Biochemical testing including enzyme activity and urine sulfatides analysis can clarify whether the individual has MLD or whether testing is indicated for a different disorder.</p><p class="headingAnchor" id="H4149301723"><span class="h2">Negative testing</span><span class="headingEndMark"> — </span>Relatives of an individual with known pathogenic variants in <em>ARSA</em> who test negative for the specific variant(s) can generally be reassured they do not carry the pathogenic variants and will not develop the disease, with caveats as described above. (See <a class="local">'How to read the report'</a> above.)</p><p>Individuals in whom MLD is clinically suspected and for whom a familial <em>ARSA</em> variant is not known may require evaluation by a neurologist and/or a genetics expert to ensure that they undergo appropriate evaluations for their symptoms. Any of the following explanations may apply:</p><p class="bulletIndent1"><span class="glyph">●</span>They may have a variant in <em>ARSA</em> that is not evaluated by their genetic test.</p><p class="bulletIndent1"><span class="glyph">●</span>They may have a variant in the other MLD gene, <em>PSAP</em>.</p><p class="bulletIndent1"><span class="glyph">●</span>They may have a variant in another gene involved in another hereditary syndrome.</p><p class="bulletIndent1"><span class="glyph">●</span>They may have an acquired condition.</p><p></p><p class="headingAnchor" id="H1546558898"><span class="h1">CONSIDERATIONS FOR RELATIVES</span></p><p class="headingAnchor" id="H1431161093"><span class="h2">First-degree relatives</span><span class="headingEndMark"> — </span>Parents of an individual who has MLD due to biallelic pathogenic variants in <em>ARSA</em> are both obligate carriers. </p><p>Full siblings of an individual with biallelic pathogenic variants in <em>ARSA</em> have a 25 percent chance of being unaffected noncarriers, a 50 percent chance of being unaffected carriers, and a 25 percent chance of being affected with MLD.</p><p>Relatives can be tested for the familial variant(s) if they have been identified. Otherwise, it is prudent to identify the variant in the affected individual first, if possible, followed by testing of first-degree relatives.</p><p class="headingAnchor" id="H452683828"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>Individuals who have had a child with MLD should be offered reproductive counseling to review their options. They may elect to use options for family planning that include adoption, in vitro fertilization (IVF) with donor gametes (donor egg or donor sperm), or IVF with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/d/html/7423.html" rel="external">"Donor insemination"</a> and  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'Oocyte donation'</a> and  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p>If they elect to have another biological child, there is a 50 percent chance the child will inherit a single pathogenic variant in <em>ARSA</em> (from one or the other parent) and a 25 percent chance they will inherit biallelic pathogenic variants (from both parents) and be affected with MLD. Prenatal diagnosis may be useful for decision-making regarding whether to continue the pregnancy if the fetus is affected. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p class="headingAnchor" id="H3643684413"><span class="h1">RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UpToDate topics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MLD diagnosis and treatment – (See  <a class="medical medical_review" href="/d/html/6195.html" rel="external">"Metachromatic leukodystrophy"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Other hereditary neuropathies – (See  <a class="medical medical_review" href="/d/html/6207.html" rel="external">"Overview of hereditary neuropathies"</a> and  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Locating an expert</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MLD specialists – MLD Foundation (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmldfoundation.org%2Fdoctors.php&amp;token=5s6wzX546K%2Btv9iW1vBuFAo9CTpXsuORZEi8CbFNzAVgNdHaI3Y0gEVdM174BIJ8&amp;TOPIC_ID=134859" target="_blank">https://mldfoundation.org/doctors.php</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=134859" target="_blank">ACMG</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=134859" target="_blank">NSGC</a>)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Shaimardanova AA, Chulpanova DS, Solovyeva VV, et al. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. Front Med (Lausanne) 2020; 7:576221.</a></li><li class="breakAll">Unique variants in the ARSA gene. Leiden Open Variation Database. Available at: https://databases.lovd.nl/shared/variants/ARSA/unique (Accessed on March 02, 2022).</li><li><a class="nounderline abstract_t">Laugwitz L, Santhanakumaran V, Spieker M, et al. Extremely low arylsulfatase A enzyme activity does not necessarily cause symptoms: A long-term follow-up and review of the literature. JIMD Rep 2022; 63:292.</a></li><li><a class="nounderline abstract_t">Harvey JS, Carey WF, Morris CP. Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype. Hum Mol Genet 1998; 7:1215.</a></li><li><a class="nounderline abstract_t">Juárez-Osuna JA, Mendoza-Ruvalcaba SC, Porras-Dorantes A, et al. Arylsulfatase A pseudodeficiency in Mexico: Enzymatic activity and haplotype analysis. Mol Genet Genomic Med 2020; 8:e1305.</a></li><li class="breakAll">Gomez-Ospina N. Arylsulfatase A deficiency. 2006 May 30 [updated 2020 Apr 30]. In: GeneReviews®, Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.</li><li><a class="nounderline abstract_t">Helman G, Van Haren K, Bonkowsky JL, et al. Disease specific therapies in leukodystrophies and leukoencephalopathies. Mol Genet Metab 2015; 114:527.</a></li><li><a class="nounderline abstract_t">Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet 2022; 399:372.</a></li></ol></div><div id="topicVersionRevision">Topic 134859 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33195324" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33195324" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35822086" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extremely low arylsulfatase A enzyme activity does not necessarily cause symptoms: A long-term follow-up and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9668161" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32431092" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Arylsulfatase A pseudodeficiency in Mexico: Enzymatic activity and haplotype analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32431092" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Arylsulfatase A pseudodeficiency in Mexico: Enzymatic activity and haplotype analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25684057" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Disease specific therapies in leukodystrophies and leukoencephalopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35065785" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
